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Abstract
Introduction: Perivascular epithelioid cell tumors are a family of rare mesenchymal tumors composed of
histologically and immunohistochemically distinctive perivascular epithelioid cells. They can originate in any visceral
organ or soft tissue and include a range of lesions such as angiomyolipoma, clear cell ‘sugar’ tumor of the lung,
lymphangioleiomyomatosis and clear cell myomelanocytic tumors of the falciparum ligament/ligament teres. Due
to their rarity and varied sites and presentation, management of these tumors remains highly challenging.
Case Presentation: A 46-year-old para 2 Caucasian woman initially presented to the general surgeons at our
hospital in North West London with abdominal pain. Laparoscopy revealed a right broad ligament hematoma,
which was thought to be iatrogenic in origin, from insertion of the Veress needle at the time of surgery, and was
managed conservatively. Upon her re-presentation two months later with severe pain, ultrasound scanning
revealed the hematoma had increased in size and she underwent a total abdominal hysterectomy and bilateral
salpingo-oophorectomy. Histology results from necrotic tissue from the hematoma led to a diagnosis of
perivascular epithelioid cell tumor. She was then referred to a tertiary oncology center, where she underwent
several further operations in an attempt to debulk the tumor for symptomatic relief of her pain, with limited
success. She is now taking the immunosuppressive drug sirolimus, which has produced a modest reduction in
tumor size. She is now 47 months on from initial presentation.
Conclusions: A literature search has revealed only six other case reports of broad ligament perivascular epithelioid
cell tumors, with varied presentations and management. The longest duration of follow-up was 21 months. Only
five other cases of perivascular epithelioid cell tumor managed with sirolimus have been reported. We therefore
feel that this report highlights some of the difficulties in diagnosing perivascular epithelioid cell tumors, and sheds
light on management strategies for a very rare gynecological tumor in addition to sharing our experience in the
use of sirolimus in its treatment.
Introduction
Perivascular epithelioid cell tumors (PEComas) are a
family of rare mesenchymal tumors composed of histo-
logically and immunohistochemically distinctive perivas-
cular epithelioid cells [1]. They can originate in any
visceral organ or soft tissue and have been reported in
the lung, pancreas, liver, kidney, bone, uterus, vulva,
heart, breast, common bile duct, bladder, skull base,
skin and soft tissue of thigh and abdominal wall, and
include a range of lesions such as angiomyolipoma, clear
cell ‘sugar’ tumor of the lung, lymphangioleiomyomato-
sis and clear cell myomelanocytic tumors of the falci-
parum ligament/ligament teres.
The majority of PEComas arise in women, and have been
reported in females ranging from 3 to 97 years of age. We
report the case of a patient with a broad ligament PEComa
whose history highlights some of the difficulties associated
with diagnosing and managing these rare tumors.
Case presentation
A 46-year-old, para 2 Caucasian woman presented to
the general surgeons at our hospital with a four-day
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S h eh a du n d e r g o n el a p a r o s c o p i cs t e r i l i z a t i o n1 3y e a r s
previously and had no medical or social history of note.
A laparoscopy was performed because appendicitis was
suspected; this revealed a right broad ligament hema-
toma. This finding was attributed to an iatrogenic injury
caused by insertion of the Veress needle during the
laparoscopy and, in the absence of peritoneal bleeding,
conservative management was initially undertaken. Two
months later, she re-presented with acute severe right
iliac fossa pain and a repeat ultrasound scan revealed an
increase in the size of the broad ligament hematoma.
She was referred to our gynecology department and
underwent a laparotomy and a total abdominal hyster-
ectomy and bilateral salpingo-oophorectomy (TAH
BSO) five months later. Intra-operative findings included
an o r m a lu t e r u sa n do v a r i e sw i t hac o p i o u sa m o u n to f
blood in the peritoneal cavity coming from a large right
broad ligament hematoma. Exploration of the hematoma
released approximately 2 L of old blood and strips of
yellow necrotic tissue, with no specific bleeding points
identified. Within four weeks, whilst awaiting reconfir-
mation of the histology results, the patient presented
with recurrence of severe lower abdominal pain; a repeat
ultrasound scan showed a reaccumulation of hematoma
in the right paravaginal space. An angiography failed to
reveal a specific bleeding point but a further large
volume of necrotic material with blood was removed by
ultrasound-guided aspiration. A histological examination
of the necrotic tissue revealed malignant polygonal
tumoral cells with ample clear or finely granular eosino-
philic cytoplasm, focally large pale nuclei with promi-
nent nucleoli and scattered mitoses, with some
abnormal forms. Immunohiostochemistry results were
positive for HMB45, melan A, caldesmon and smooth
muscle actin, leading to a final diagnosis of broad liga-
ment PEComa.
Further management was undertaken in a tertiary
oncology center (Royal Marsden Hospital, London), and
two months after the TAH BSO, a full body computed
tomography (CT) scan revealed a 10 × 10 × 10 cm pel-
vic mass to the right of the midline with a satellite
lesion on the left. In addition, a right hydronephrosis
secondary to the mass was diagnosed and managed with
nephrostomy and ureteric stent insertion. The patient
underwent palliative radiotherapy, after which the
nephrostomy was removed. Her pelvic pain did not
respond to the radiotherapy and has remained the main
issue.
At 10 months after her initial presentation, an exami-
nation under anesthesia (EUA) and cystoscopy was per-
formed. Operative findings included a large pelvic
tumor closely related to the superior and anterior
aspects of the vagina and distorting it. The bladder
mucosa appeared normal except for radiation changes.
At this stage, further surgery was considered to be a
hazardous option and symptomatic management was
continued.
Four months after the EUA and cystoscopy the pain
had become unbearable for our patient and she under-
went an EUA, sigmoidoscopy, cystoscopy and laparo-
scopy, which revealed a large retroperitoneal tumor on
the right pelvic side wall extending down the right vagi-
nal wall and distorting the vagina and bladder. No
tumor breach was seen on cystoscopy or sigmoidoscopy.
A fistulous connection was found between the tumor
and vagina and the bowel was adherent to the tumor
mass. A histological examination of the tumor showed
features similar to the first sample, with scattered malig-
nant epithelioid malignant cells with enlarged hyper-
chromatic pleomorphic nuclei containing abundant
finely granular eosinophilic cytoplasm and distinct cell
boundaries, and was consistent, as before, with malig-
nant PEComa. There were no malignant cells in the
peritoneal washings sent.
One month later, repeat CT imaging showed no
tumor progression over the previous three months and
at this stage her symptoms were tolerable with opioid
analgesia. However, four months after this, she devel-
oped left-sided hydronephrosis and opted to have a ure-
teric stent rather than other surgical management
options.
The patient agreed to consider the option of sirolimus
one month after undergoing stenting of her left ureter,
based on a report of clinical benefit in a small series of
patients with PEComas treated in the USA [2]. It was
hoped that treatment with sirolimus might result in suf-
ficient tumor shrinkage to facilitate a subsequent
operation.
Over the subsequent six months, she required numer-
ous hospital admissions with urinary tract infections.
During one of these episodes, she was admitted to the
coronary care unit with dilated cardiomyopathy and was
diagnosed with nephrogenic diabetes insipidus requiring
treatment with desmopressin.
The patient remained symptomatic with low abdom-
inal and deep pelvic pain and multi-drug resistant recur-
rent urinary tract infections, along with radiation
induced colitis. A CT scan performed a year after start-
ing sirolimus showed a modest reduction in tumor size
and the findings were unchanged on further imaging
two months later. Three months after this, she under-
went surgery in the hope of resecting the tumor. Unfor-
tunately, extensive fibrosis was found making it
impossible to identify the pelvic vessels, hence the
tumor resection was abandoned. The fibrosis extended
up to the kidneys but the ureters were freed from the
fibrous tissue and an ileal conduit was fashioned
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time there has only been one minor episode of urinary
tract infection, but pain continues to be a problem.
A recent MRI scan (see Figures 1 and 2) shows that
over the entire treatment period with sirolimus, a sub-
stantial degree of tumor shrinkage has occurred, from a
maximum diameter of 92 mm a year after initial presen-
tation (prior to starting sirolimus) to 53 mm following
two years of sirolimus treatment. The patient has con-
tinued with sirolimus treatment, currently at a dose of 4
mg daily, 5 mg being associated with mouth ulceration.
Discussion
A diagnosis of PEComa is made on the basis of histolo-
gical and immunohistochemical findings. Basic charac-
teristic features of perivascular epithelioid cells include
abundant clear to eosinophilic granular cytoplasm with
an immunoprofile of HMB45 positivity and lack of
expression of S-100 protein, though the latter is positive
in a minority of cases. Other features include expression
of another melanoma-associated antigen melan A, coex-
pression of muscle cell markers without cytokeratin
expression and the presence of melanosomes or pre-
Figure 1 MRI scan of the pelvis prior to starting sirolimus, following total abdominal hysterectomy and bilateral salpingo-
oophorectomy (TAH BSO), demonstrating the perivascular epithelioid cell tumor (PEComa) measuring 92 mm.
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HMB45, melan A and smooth muscle actin.
PEComas of the gynecological tract account for
approximately 40% of reported cases [3]. In the pelvis,
the uterine body appears to be the most prominent site
of this rare tumor, with smaller numbers of PEComas
reported in the broad ligament, pelvic soft tissue, cervix,
vagina and the urinary bladder [4-7].
Morphologically there are two types, epithelioid and
spindle cell. In the epithelioid type the cells have clear
to lightly eosinophilic, finely granular cytoplasm and
may form thick-walled pseudo blood vessels. The spin-
dle cell type, which has fascicles and nests of spindle
cells with clear to lightly eosinophilic cytoplasm arrayed
around an elaborate capillary sized vascular network,
forms the majority of cases [4].
Uterine PEComas are characterized by perivascular
epithelioid cells that are HMB45 positive/S-100 protein
negative with abundant clear to eosinophilic granular
cytoplasm, but there may be an overlap with some
epithelioid smooth muscle tumors of the uterus making
the initial diagnosis difficult [8]. The patient’sl e s i o ni s
Figure 2 MRI scan of the pelvis after two years on sirolimus, demonstrating a reduction in size of the perivascular epithelioid cell
tumor (PEComa) (measuring 53 mm) following treatment with sirolimus.
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should be excluded in uterine lesions are endometrial
stromal sarcoma and paraganglioma [9].
The patient had a broad ligament PEComa, of which
we were able to identify six other reported cases on a
literature search of English language articles performed
using the search words of ‘broad ligament’ and
‘PEComa’ in January 2011 [3,7,9-12]. The age at presen-
tation in these reports ranged from 12 to 51 years.
Reported clinical presentation varied from incidental
finding of abdominal mass, lower abdominal pain and/
or leg pain to abnormal uterine bleeding in a young
woman. The tumor typically achieves a large size by the
time of diagnosis, representing the difficulty of clinically
recognizing these tumors, as was seen in our patient’s
case.
The current classification of PEComas is based on the
morphology and the location of the tumor but this is
not an indicator of prognostic outcome. To overcome
this, Folpe et al. have proposed criteria for classification
of these tumors into three groups: benign, of uncertain
malignant potential and malignant, based on tumor size,
level of infiltration, nuclear grade, cellularity, mitotic
rate, necrosis and vascular invasion [3]. Using these cri-
teria, the patient’s histology and immunohistochemistry
(as detailed above) favor the lesion being classified as a
malignant PEComa, and although the tumor has not
metastasized, it has behaved in a locally malignant fash-
ion. However, long-term follow-up of a larger number
of patients will be required prior to the proposed classi-
fication being used as a prognostic indicator.
Duration of follow-up in the literature has varied from
eight to 18 months; it is now 47 months since this
patient’s TAH BSO with persistent evidence of tumor
following an initial diagnosis of malignant PEComa.
Reported management mainly includes surgical excision,
but this ranged from removal of mass, salpingo-oophor-
ectomy to total abdominal hysterectomy and bilateral sal-
pingo-oophorectomy. In addition, one patient had pelvic
radiation along with the TAH BSO and another required
re-excision, though local recurrence occurred in three out
of six patients [3,11,12]. Our patient underwent initial
TAH BSO, followed by USS-guided (ultrasound scan)
aspiration of hematoma, pelvic radiation and a trial of siro-
limus, which has resulted in some tumor shrinkage that
has continued. She has remained symptomatic throughout,
mainly from pelvic pain.
Sirolimus is an immunosuppressive agent approved by
the US Food and Drug administration for use in the man-
agement of renal transplant, renal cell carcinoma and
acute myeloid leukemia [13,14]. It inhibits the activation
and proliferation of T lymphocytes in response to stimula-
tion by antigens and cytokines (interleukin (IL)-2, IL-4,
and IL-15) while also inhibiting antibody production. At a
cellular level, it inhibits the activation of the mammalian
target of rapamycin (mTOR), a key regulatory kinase, lead-
ing to suppression of cytokine-driven T cell proliferation
and inhibition of cell cycle from the G1 to the S phase. Sir-
olimus (rapamycin) is of course the archetypal inhibitor of
mTOR, which in cancer cells is associated with increased
angiogenesis, stimulation of protein synthesis and inhibi-
tion of cell death. PEComas are associated with mutations
or deletions of tuberous sclerosis associated genes TSC1
or TSC2, which act as tumor suppressor genes by regulat-
ing mTOR. Their loss results in upregulation of the
mTOR pathway. An encouraging recent case series of
three patients with advanced malignant PEComa treated
with sirolimus reported radiological response and disease
stabilization [2]. There was evidence in archive material of
changes in TSC1 or TSC2 in these tumors but these find-
ings were inconsistent and indicate the need for further
investigation of the mechanism of mTOR activation in
these diseases [2].
Italiano et al. also reported a series of two patients
with malignant metastatic uterine PEComas, one treated
successfully with the mTOR inhibitor temsirolimus
(now disease free following resection of her pulmonary
metastasis) and the other showing a partial response fol-
lowed by disease progression, with the temsirolimus
being stopped at 22 weeks because of this [15].
Subbiah et al. subsequently reported a case of a 58-
year-old woman who underwent surgical resection of a
malignant PEComa arising from the retroperitoneum
above the right kidney. She subsequently developed
hepatic metastases whilst on doxorubicin chemotherapy.
Following radiotherapy and further chemotherapy, she
was treated with temsirolimus but her disease continued
to progress and at the time of reporting, she had elected
to undergo palliative care [16].
A radiological response to sirolimus was seen in our
patient with epithelioid PEComa, as demonstrated by
the MRI images shown in Figures 1 and 2.
Conclusions
In summary, PEComas are rare gynecological tumors,
associated with activation of mTOR. Their clinical beha-
vior and the precise molecular mechanisms driving
these diseases require further investigation. More thor-
ough reporting and long-term study of all known cases
will help us to fully understand, define and manage
these tumors. In particular, with regard to mTORC1
inhibitors, accurate histological description of tumor
type (epithelioid or spindle cell) would be valuable in
further defining and targeting the use of this agent.
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